OTC Markets OTCPK - Delayed Quote USD

(STME)

Compare
0.0510 -0.5340 (-91.28%)
As of December 11 at 9:30:01 AM EST. Market Open.
Loading Chart for STME
DELL
  • Previous Close 0.5850
  • Open 0.0510
  • Bid 0.0751 x --
  • Ask 0.5850 x --
  • Day's Range 0.0510 - 0.0510
  • 52 Week Range 0.0015 - 3.4200
  • Volume 170
  • Avg. Volume 724
  • Market Cap (intraday) 1.011M
  • Beta (5Y Monthly) 32.86
  • PE Ratio (TTM)
  • EPS (TTM) 0.0000
  • Earnings Date Jan 14, 2025 - Jan 20, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

StimCell Energetics Inc., a biotech company, discovers, develops, and commercializes therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, high blood pressure, neuropathy, and kidney functions in the United States. The company develops and manufactures eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and eBalance Home System for home use for general wellness and pain management treatment, which are controlled by the eBalance Console that acts as the central controller for three pre-programmed microcurrent algorithms, including wellness, pain management, and dual. It also develops eBalance Home and eBalance Pro System for temporary relief of shoulder, waist, back, neck, arms, and legs. The company was formerly known as Cell MedX Corp. and changed its name to StimCell Energetics Inc. in November 2024. StimCell Energetics Inc. was incorporated in 2010 and is headquartered in Carson City, Nevada.

stimcell.com

--

Full Time Employees

May 31

Fiscal Year Ends

Recent News: STME

View More

Performance Overview: STME

Trailing total returns as of 12/12/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

STME
84.55%
S&P 500
27.42%

1-Year Return

STME
63.83%
S&P 500
31.48%

3-Year Return

STME
98.30%
S&P 500
28.98%

5-Year Return

STME
98.10%
S&P 500
93.46%

Compare To: STME

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: STME

View More

Valuation Measures

Annual
As of 7/12/2024
  • Market Cap

    1.01M

  • Enterprise Value

    1.31M

  • Trailing P/E

    30.12

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    34.55k

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    103.69k

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -421.58%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -132.45k

  • Diluted EPS (ttm)

    0.0000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    20.55k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -1.11M

Research Analysis: STME

View More

Company Insights: STME

Research Reports: STME

View More